| RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - March 27, 2012) - Adherex Technologies Inc. (TSX:AHX)(PINKSHEETS:ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today reported its financial results for the fiscal year ended December 31, 2011. All amounts are in U.S. dollars unless otherwise specified. Recent Developments Eniluracil Phase II Study Update - Enrollment in the Company's Phase II clinical trial for Metastatic Breast ...continued ADHXF AHX:CA Healthcare Drugs |
Tuesday, March 27, 2012
Adherex Reports Recent Developments and Fiscal Year Ended December 31, 2011 Financial Results
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment